Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system
This study identified distinct associations between different dual ICIs treatment strategies and various cardiac adverse events. We further identified potential risk factors and co-reported symptoms of cardiotoxicity, which may aid in the early diagnosis and monitoring of ICI-associated cardiac adverse events.
Authors
- Shuimei Luo (ORCID: https://orcid.org/0000-0002-9103-6986)
- Lei Shi (ORCID: https://orcid.org/0000-0002-3820-3693)
- Zequn Sun (ORCID: https://orcid.org/0000-0003-4177-9199)
- H. Xia
- Yu Chen
- Huazhen Xiao
- Mengru Quan
- Jing Lin
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1093/ehjcvp/pvag006
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 24.20